Abstract
BACKGROUND: Myeloid sarcoma (MS) as the initial manifestation of chronic myeloid leukemia (CML), while the bone marrow (BM) remains in the chronic phase, is exceedingly rare. CASE PRESENTATION: We report two cases of MS initially presented with hip pain and soft tissue masses. Both patients had unremarkable complete blood counts and BM morphology, and initial core needle biopsies were misinterpreted as non-Hodgkin lymphoma. Further cytogenetic and molecular analyses, however, identified the Philadelphia chromosome, BCR::ABL rearrangement, and mutations in TP53, KMT2D and STAG2, establishing the diagnosis of MS secondary to CML in extramedullary blast phase. Both patients received tyrosine kinase inhibitors with or without chemotherapy, nevertheless, their disease progressed rapidly, resulting in death within one year. CONCLUSION: Through a comprehensive literature review, we identified 33 additional reported cases with the same diagnosis. This disease predominantly affects middle-aged men, with bone and parosteal soft tissues being the most common involved extramedullary site. Such patients may constitute a biologically distinct subgroup and, in some reports, have shown relatively favorable outcomes. However, our cases follow an aggressive clinical course, possibly influenced by high-risk molecular features. Large-scale clinical studies are required to clarify the biological heterogeneity of this subgroup and to optimize therapeutic strategies.